Indoco Gets US FDA Nod for Allopurinol 200 mg Tablets

Key Highlights-

• Indoco receives US FDA approval for generic Allopurinol 200 mg
• The drug is a generic equivalent of Zyloprim by Casper Pharma
• This approval supports Indoco’s expansion in the US market

Indoco Remedies Ltd., a research focused pharmaceutical company, has received final approval from the US Food and drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for allopurinol tablets USP 200 mg. This has been a very positive entry into the market as a generic version of Casper Pharma’s Zyloprim 200 mg in the U.S.

Allopurinol is commonly prescribed to reduce high uric acid levels, and for patients who are undergoing cancer treatment or dealing with kidney stones.

This approved product will be manufactured at Indoco’s Verna, Goa facility in India. Remarking on the development, Managing Director Aditi Panandikar said, “This milestone not only reflects Indoco’s high manufacturing standards but also strengthens our growth strategy in a key global market like the US.”

Also Read: FDA Advisers Urge COVID Shots to Target JN.1 Variant Strains

With a global track, Indoco Remedies reports annual revenues of US 180 million dollars and employs over 6,000 professionals, including more than 400 scientists.